Home / Health / Weight Loss Drugs Cut Breast Cancer Risk
Weight Loss Drugs Cut Breast Cancer Risk
2 Jun
Summary
- GLP-1 drugs like Ozempic linked to 30% breast cancer risk reduction.
- Study observed over 110,000 overweight American women.
- Researchers exploring drugs as potential cancer prevention tools.
Women taking popular GLP-1 weight loss medications, including Ozempic and Wegovy, showed a 30 percent reduced risk of developing breast cancer, according to new research from the University of Pennsylvania Perelman School of Medicine. This finding adds to evidence suggesting these drugs may offer broader health benefits.
The observational study tracked over 110,000 overweight American women aged 45-80 between 2022 and 2025. While not definitively proving causation, the results prompt further investigation into GLP-1s as potential cancer prevention tools.
GLP-1 drugs mimic a hormone that regulates blood sugar and appetite, leading to significant weight loss. Since obesity is a known risk factor for breast cancer, the drugs' ability to combat obesity and inflammation may contribute to the observed reduced risk.
Researchers are planning clinical trials to further assess these effects, particularly in women at higher risk for breast cancer. The ultimate goal is to discover better methods for preventing breast cancer, complementing existing survival improvements.
